Neumentum, Inc.

neumentum.com

Neumentum is developing and plans to commercialize products that have the potential to effectively treat pain, without the risks of abuse, misuse and diversion seen with opioid analgesics. Neumentum’s lead product candidate, NTM-001 (novel, alcohol-free formulation of ketorolac in a pre-mixed bag for continuous IV infusion), has the potential to treat moderately severe acute pain that requires analgesia at the opioid level for up to 24 hours, usually in a postoperative setting, and to reduce the need for opioids.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ACACIA PHARMA COMPLETES DRAWDOWN FROM €25 MILLION LOAN FACILITY FROM COSMO PHARMACEUTICALS TO SUPPORT US LAUNCHES OF BARHEMSYS® AND BYFAVO™

Acacia Pharma Group plc | October 12, 2020

news image

Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that it has drawn down the remaining €10 million available under its unsecured €25 million loan facility with Cosm...

Read More

RESEARCH, PHARMA TECH

IONIS PHARMA'S EPLONTERSEN FOR ATTRV-PN GETS FDA'S NDA ACCEPTANCE

Ionis Pharmaceuticals, Inc. | March 10, 2023

news image

Ionis Pharmaceuticals, a leading RNA-targeted therapy firm, recently announced that the USFDA has accepted for review a new drug application (NDA) for eplontersen. Eplontersen is an investigational antisense medicine designed to reduce the production of transthyretin (TTR) protein and treat hereditary and non-hereditary forms of ATTR amyloidosis (ATTR). The NDA has been given a Prescription Drug User Fee Act (PDUFA) action date of December 22, 2023. The FDA has declared that no ...

Read More

BUSINESS INSIGHTS

TRIMAS CLOSES ON ACQUISITION OF OMEGA

TriMas | December 21, 2021

news image

TriMasannounced that it has closed the acquisition of Omega Plastics (“Omega”), a manufacturer of custom components and tooling for medical, as well as industrial applications, adding to TriMas’ Packaging group. Omega leverages its core injection molding capabilities, ISO Class 8 clean room and advanced in-house tool making capabilities, to provide its customers a faster product development cycle, from prototype development, testing and validation, to short...

Read More

BUSINESS INSIGHTS

CEDARS-SINAI MEDICAL CENTER AND AIKIDO PHARMA INC. TO CODEVELOP NOVEL IMMUNO-ONCOLOGY CANCER TREATMENT

AIkido Pharma Inc. | March 15, 2022

news image

AIkido Pharma Inc. announced that the Company and Cedars-Sinai Medical Center have agreed under their Master Collaboration Agreement to co-fund and codevelop a novel immuno-oncology treatment designed to promote the destruction of cancer cells by a patient's own "killer" T-cells. The Company and Cedars-Sinai will share costs, expenses and management of the drug co-development and will leverage the talent of Cedars-Sinai Technology Ventures and the lead scientists who...

Read More
news image

ACACIA PHARMA COMPLETES DRAWDOWN FROM €25 MILLION LOAN FACILITY FROM COSMO PHARMACEUTICALS TO SUPPORT US LAUNCHES OF BARHEMSYS® AND BYFAVO™

Acacia Pharma Group plc | October 12, 2020

Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that it has drawn down the remaining €10 million available under its unsecured €25 million loan facility with Cosm...

Read More
news image

RESEARCH, PHARMA TECH

IONIS PHARMA'S EPLONTERSEN FOR ATTRV-PN GETS FDA'S NDA ACCEPTANCE

Ionis Pharmaceuticals, Inc. | March 10, 2023

Ionis Pharmaceuticals, a leading RNA-targeted therapy firm, recently announced that the USFDA has accepted for review a new drug application (NDA) for eplontersen. Eplontersen is an investigational antisense medicine designed to reduce the production of transthyretin (TTR) protein and treat hereditary and non-hereditary forms of ATTR amyloidosis (ATTR). The NDA has been given a Prescription Drug User Fee Act (PDUFA) action date of December 22, 2023. The FDA has declared that no ...

Read More
news image

BUSINESS INSIGHTS

TRIMAS CLOSES ON ACQUISITION OF OMEGA

TriMas | December 21, 2021

TriMasannounced that it has closed the acquisition of Omega Plastics (“Omega”), a manufacturer of custom components and tooling for medical, as well as industrial applications, adding to TriMas’ Packaging group. Omega leverages its core injection molding capabilities, ISO Class 8 clean room and advanced in-house tool making capabilities, to provide its customers a faster product development cycle, from prototype development, testing and validation, to short...

Read More
news image

BUSINESS INSIGHTS

CEDARS-SINAI MEDICAL CENTER AND AIKIDO PHARMA INC. TO CODEVELOP NOVEL IMMUNO-ONCOLOGY CANCER TREATMENT

AIkido Pharma Inc. | March 15, 2022

AIkido Pharma Inc. announced that the Company and Cedars-Sinai Medical Center have agreed under their Master Collaboration Agreement to co-fund and codevelop a novel immuno-oncology treatment designed to promote the destruction of cancer cells by a patient's own "killer" T-cells. The Company and Cedars-Sinai will share costs, expenses and management of the drug co-development and will leverage the talent of Cedars-Sinai Technology Ventures and the lead scientists who...

Read More